TITLE

In search of a cause of cryptogenic fibrosing alveolitis (CFA)*: one initiating factor or many?

AUTHOR(S)
Turner-Warwick, Margaret
PUB. DATE
August 1998
SOURCE
Thorax;Aug1998, pS3
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
66876991

 

Related Articles

  • Rising mortality from cryptogenic fibrosing alveolitis. Johnston, Ian; Britton, John; Kinnear, William; Logan, Richard // BMJ: British Medical Journal (International Edition);11/3/90, Vol. 301 Issue 6759, p1017 

    Examines the mortality rate caused by cryptogenic fibrosing alveolitis in Great Britain. Identification of factors important in the etiology of the disease; Assessment of the validity of death certification of the disease; Treatment and management of the disease.

  • Cryptogenic Fibrosing Alveolitis Predating Ulcerative Colitis. De Llano, Luis A. Pérez; Lancho, Angel; Del Cerro, J. L. Soilán; López-Rosés, Leopoldo // American Journal of Gastroenterology;Apr1996, Vol. 91 Issue 4, p822 

    Presents a letter to the editor on cryptogenic fibrosing alveolitis predating ulcerative colitis.

  • What is this thing called CFA? Wells, A. U.; Hansell, D. M.; Nicholson, A. G. // Thorax;Jan2007, Vol. 62 Issue 1, p3 

    The article discusses various reports published within the issue, including one by R. Rudd, R.J. Prescott and JC Chalmers regarding cryptogenic fibrosing alveolitis.

  • Autoantibodies in cryptogenic fibrosing alveolitis. Singh, Suveer; Du Bois, Ron // Respiratory Research;2001, Vol. 2, p61 

    The pathogenesis of cryptogenic fibrosing alveolitis (CFA) involves injury, an immune/inflammatory response and fibrosis. The cause of the injury is unknown, but the identification of serum autoantibodies makes an autoimmune aetiology attractive. The core study on which this commentary is based...

  • Idiopathic pulmonary fibrosis/cryptogenic fibrosing alveolitis. Fellrath, J. M.; Du Bois, R. M. // Clinical & Experimental Medicine;Sep2003, Vol. 3 Issue 2, p65 

    Idiopathic pulmonary fibrosis (IPF), synonymous with cryptogenic fibrosing alveolitis (CFA), is a progressive and usually fatal disease of unknown cause characterized by sequential acute lung injury with subsequent scarring and end-stage lung disease. Historically, IPF/CFA encompassed a...

  • Pulmonary Fibrosis.  // Current Medical Literature: Respiratory Medicine;2010, Vol. 24 Issue 1, p23 

    The article reviews several studies on pulmonary fibrosis. It cites an investigation on the effect of bosentan in patients with idiopathic pulmonary fibrosis (IPF) in the Bosentan Use in Interstitial Lung Disease-1 (BUILD-1) trial which note that endothelin antagonists do not have any proven...

  • Minerva.  // BMJ: British Medical Journal (International Edition);04/11/98, Vol. 316 Issue 7138, p1178 

    Presents information on developments in medicine. Information on injuries from snowmobiles; Account on an approach for treating metastatic breast cancer; Survival period of patients with cryptogenic fibrosing alveolitis.

  • Development of cryptogenic fibrosing alveolitis during pregnancy. Densem, Cameron; Niven, Robert; Barber, Philip; Bishop, Pau // Journal of the Royal Society of Medicine;Nov1998, Vol. 91 Issue 11, p591 

    The article reports on the case of a 29-year-old woman who developed cryptogenic fibrosing alveolitis (CFA) during pregnancy. There was no sputum production or chest pain. She was an ex-smoker of 20 cigarettes per day for 15 years but have given up at the start of the pregnancy. She was treated...

  • What causes cryptogenic fibrosing alveolitis? A case-control study of environmental exposure to dust. Scott, Jonathan; Johnston, Ian; Britton, John // BMJ: British Medical Journal (International Edition);11/3/90, Vol. 301 Issue 6759, p1015 

    Examines the etiology of cryptogenic fibrosing alveolitis in Nottingham, England. Role of the occupational and domestic exposure to dust for the development of the disease; Survival of patients after a month of diagnosed; Evaluation of the restrictive pulmonary function test for the investigation.

  • Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease. Bernstein, R.M.; Morgan, S.H.; Chapman, J.; Bunn, C.C.; Mathews, M.B.; Turner-Warick, M.; Hughes, G.R.V. // British Medical Journal (Clinical Research Edition);7/21/1984, Vol. 289 Issue 6438, p151 

    Discusses the function of anti-jo-1 antibody in patients with myositis and cryptogenic fibrosing alveolitis in Great Britain. Definition of myositis; Identification of the antibody by counterimmunoelectrophoresis; Usage of cytotoxic drugs.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics